PT - JOURNAL ARTICLE AU - Dipender Gill AU - Stephen Burgess AU - Xue Li AU - Ville Karhunen AU - Alan Cameron AU - Verena Zuber AU - Philip S. Tsao AU - Derek Klarin AU - VA Million Veteran Program AU - Evangelos Evangelou AU - Paul Elliott AU - Scott M. Damrauer AU - Terry Quinn AU - Abbas Dehghan AU - Evropi Theodoratou AU - Jesse Dawson AU - Ioanna Tzoulaki TI - Genetically predicted serum urate, blood pressure and cardiovascular disease: an updated Mendelian randomization investigation AID - 10.1101/2019.12.11.19014472 DP - 2019 Jan 01 TA - medRxiv PG - 2019.12.11.19014472 4099 - http://medrxiv.org/content/early/2019/12/15/2019.12.11.19014472.short 4100 - http://medrxiv.org/content/early/2019/12/15/2019.12.11.19014472.full AB - Background Elevated serum urate has been associated with an increased risk of cardiovascular disease (CVD), but it is not known whether this relationship is causal, non-linear or sex-specific. Basic science and clinical trial data have supported an effect of serum urate on systolic blood pressure (SBP), which may in turn mediate an effect on CVD risk.Methods Using recently available data from the Million Veterans Program and UK Biobank, we applied improved genetic instruments for serum urate in one and two-sample Mendelian randomization (MR) analyses to investigate for effects on risk of coronary heart disease (CHD), peripheral artery disease (PAD), and stroke. Potential mediation through SBP was explored, as well as evidence of non-linear and sex-specific effects. We performed a number of sensitivity analyses using different MR methodologies and populations to investigate consistency of our findings.Results Higher genetically predicted serum urate was associated with an increased risk of CHD (odds ratio [OR] per 1-standard deviation increase in genetically predicted urate 1.19, 95% confidence interval [CI] 1.10-1.30, P=4×10−5), PAD (OR 1.12, 95% CI 1.03-1.21, P=9×10−3), and stroke (OR 1.11, 95% CI 1.05-1.18, P=2×10−4). Similar estimates were produced when applying MR methods that make distinct assumptions, or when considering different populations. SBP was estimated to mediate 29%, 44% and 45% of the effect of urate on CHD, PAD and stroke respectively. There was no evidence of non-linear or sex-specific effects of genetically predicted urate on CVD risk.Conclusions Using contemporary data and MR methods, we provide support for an effect of serum urate on CVD risk that may partly be mediated through SBP. High-quality trials are necessary to provide definitive evidence on the cardiovascular benefit of urate lowering.Competing Interest StatementJD and TQ have received charitable research income to conduct clinical trials of allopurinol use in people with stroke. The remaining authors have no conflicts of interest to declare.Funding StatementThis work was supported by funding from the US Department of Veterans Affairs Office of Research and Development, Million Veteran Program Grant MVP003 (I01-BX003362). This publication does not represent the views of the Department of Veterans Affairs of the US Government. DG is funded by the Wellcome 4i Clinical PhD Program at Imperial College London. VK is funded by the European Union's Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant (721567). PE acknowledges support from the Medical Research Council (MR/S019669/1), the National Institute for Health Research Imperial Biomedical Research Centre, Imperial College London (RDF03), the UK Dementia Research Institute (DRI) at Imperial College London funded by UK DRI Ltd (funded by Medical Research Council, Alzheimer’s Society, Alzheimer’s Research UK), and Health Data Research (HDR) UK London funded by HDR UK Ltd (funded by a consortium led by the Medical Research Council 1004231). SMD was supported by the Department of Veterans Affairs Office of Research and Development (IK2-CX001780). ET is funded by a Cancer Research UK Career Development Fellowship (C31250/A22804). The MEGASTROKE project received funding from sources specified at http://www.megastroke.org/acknowledgments.html. Details of all MEGASTROKE authors are available at http://www.megastroke.org/authors.html.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data used in this work are either publicly accessible or available on request from their original studies, which obtained appropriate patient consent and ethical approval. The UK Biobank data were accessed through application 236. All results generated in this work are presented in either the manuscript or its supplementary files.